PLK1 and its role in the evolving landscape of KRAS-mutated colorectal cancer

被引：1
|
作者：
Harvey, Harry [1 ]
Chen, Eric Xueyu [1 ]
机构：
[1] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, 7-824,700 Univ Ave, Toronto, ON M5G 1Z5, Canada
来源：
JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2024年 / 15卷 / 04期
关键词：
Kirsten rat sarcoma virus (KRAS); colorectal cancer (CRC); targeted therapy; RAS; INHIBITOR; FOLFIRI; BEVACIZUMAB; GEMCITABINE; COMBINATION; ISIS-2503;
D O I：
10.21037/jgo-24-323
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1987 / 1992
页数：6
相关论文
共 50 条
  • [21] Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer
    Goel, Sanjay
    Ocean, Allyson J.
    Parakrama, Ruwan Y.
    Ghalib, Mohammad H.
    Chaudhary, Imran
    Shah, Umang
    Viswanathan, Sengottuvel
    Kharkwal, Himanshu
    Coffey, Matthew
    Maitra, Radhashree
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (05) : 1148 - 1156
  • [22] Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
    Wang, Jieqiong
    Hu, Kewen
    Guo, Jiawei
    Cheng, Feixiong
    Lv, Jing
    Jiang, Wenhao
    Lu, Weiqiang
    Liu, Jinsong
    Pang, Xiufeng
    Liu, Mingyao
    NATURE COMMUNICATIONS, 2016, 7
  • [23] Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
    Jieqiong Wang
    Kewen Hu
    Jiawei Guo
    Feixiong Cheng
    Jing Lv
    Wenhao Jiang
    Weiqiang Lu
    Jinsong Liu
    Xiufeng Pang
    Mingyao Liu
    Nature Communications, 7
  • [24] p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer
    Gian Luca Rampioni Vinciguerra
    Alessandra Dall’Acqua
    Ilenia Segatto
    Maria Chiara Mattevi
    Francesca Russo
    Andrea Favero
    Roberto Cirombella
    Giorgia Mungo
    Davide Viotto
    Javad Karimbayli
    Margherita Pesce
    Andrea Vecchione
    Barbara Belletti
    Gustavo Baldassarre
    Cell Death & Disease, 12
  • [25] p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer
    Vinciguerra, Gian Luca Rampioni
    Dall'Acqua, Alessandra
    Segatto, Ilenia
    Mattevi, Maria Chiara
    Russo, Francesca
    Favero, Andrea
    Cirombella, Roberto
    Mungo, Giorgia
    Viotto, Davide
    Karimbayli, Javad
    Pesce, Margherita
    Vecchione, Andrea
    Belletti, Barbara
    Baldassarre, Gustavo
    CELL DEATH & DISEASE, 2021, 12 (10)
  • [26] Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation
    Morris, Van Karlyle
    Overman, Michael J.
    Eng, Cathy
    Sanchez, Eduardo Vilar
    Morelli, Maria
    Jiang, Zhiqin
    Luthra, Rajyalakshmi
    Maru, Dipen M.
    Meric-Bernstam, Funda
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Everolimus inhibits invasion and angiogenesis in a KRAS-mutated mesenchymal-differentiated colorectal cancer xenografts
    Tijeras-Raballand, Annemilai
    Dos Santos, Celia
    Serova, Maria
    Riveiro, Maria Eugenia
    de Gramont, Armand
    Faivre, Sandrine
    Raymond, Eric
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [28] KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    Spindler, K. G.
    Appelt, A. L.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 3067 - 3072
  • [29] Japanese experience with hepatic resection of KRAS-mutated colorectal liver metastases
    Shindoh, Junichi
    CHINESE CLINICAL ONCOLOGY, 2019, 8 (05)
  • [30] The role of PLK1 in cancer exhibiting chromosomal instability
    Strebhardt, Klaus
    Raab, Monika
    Sanhaji, Mourad
    MOLECULAR & CELLULAR ONCOLOGY, 2018, 5 (06)
12345